Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 12, 2013, Pages 2548-2557

  Creech, C Buddy ^a   Dekker, Cornelia L ^b   Ho, Dora ^b   Phillips, Shanda ^b   Mackey, Sally ^b   Murray Krezan, Cristina ^c   Pau, Maria Grazia ^d   Hendriks, Jenny ^d   Brown, Valerie ^e   Dally, Leonard G ^e   Versteege, Isabella ^d   Edwards, Kathryn M ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^d CRUCELL HOLLAND BV   (Netherlands)

^e EMMES CORPORATION   (United States)

Author keywords

Adenovirus; Circumsporozoite; Malaria; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CIRCUMSPOROZOITE PROTEIN; CREATININE; IMMUNOGLOBULIN G ANTIBODY; MALARIA VACCINE; NEUTRALIZING ANTIBODY; PLACEBO;

ADENOVIRUS TYPE 35; ADULT; ANEMIA; ANTIBODY RESPONSE; ANTIBODY TITER; ARM PAIN; ARM WEAKNESS; ARTICLE; BALANCE DISORDER; BRACHIAL PLEXUS NEUROPATHY; CELLULAR IMMUNITY; CERVICAL LYMPHADENOPATHY; CHILL; CONTROLLED STUDY; DIAPHORESIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHILIA; FAINTNESS; FEMALE; FEVER; HAND PAIN; HAND PARESTHESIA; HEADACHE; HERPES SIMPLEX; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; MALAISE; MALE; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NORMAL HUMAN; PARESTHESIA; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PROTEINURIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA; TONGUE DISEASE; TONGUE PRURITUS; UNSPECIFIED SIDE EFFECT;

ADENOVIRUS; CIRCUMSPOROZOITE; MALARIA; VACCINE;

ADENOVIRUSES, HUMAN; ADOLESCENT; ADULT; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; DRUG CARRIERS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; HUMANS; MALARIA; MALARIA VACCINES; MIDDLE AGED; PLACEBOS; PROTOZOAN PROTEINS; TREATMENT OUTCOME; VACCINATION; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 84893059821     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.26038     Document Type: Article

References (41)

1. Carter R, Mendis KN. Evolutionary and historical aspects of the burden of malaria. Clin Microbiol Rev 2002; 15: (Pubitemid 41184079)
2. Snow RW, Guerra CA, Noor A.M., Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005; 434: 214-7; PMID: 15759000; http://dx.doi.org/10.1038/nature03342 (Pubitemid 40388051)
3. World Health Organization. WHO Facts on Malaria. 2013.
4. Mandell GL, Douglas RG, Bennett J.E., Dolin R. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2005.
5. John CC, Moormann AM, Pregibon D.C., Sumba PO, McHugh MM, Narum DL, Lanar D.E., Schluchter MD, Kazura J W. Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium fal-ciparum antigens and protection from infection. Am J Trop Med Hyg 2005; 73: 222-8; PMID: 16014863 (Pubitemid 41278777)
6. John CC, Tande AJ, Moormann A.M., Sumba PO, Lanar DE, Min XM, Kazura JW. Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children. J Infect Dis 2008; 197: 519-26; PMID: 18275273; http://dx.doi.org/10.1086/526787 (Pubitemid 351321528)
7. John CC, Zickafoose JS, Sumba P.O., King CL, Kazura JW. Antibodies to the Plasmodium falci-parum antigens circumsporozoite protein, throm-bospondin- related adhesive protein, and liver-stage antigen 1 vary by ages of subjects and by season in a highland area of Kenya. Infect Immun 2003; 71: 4320-5; PMID: 12874308; http://dx.doi.org/10.1128/IAI.71.8.4320-4325.2003 (Pubitemid 36919895)
8. Agnandji ST, Lell B, Soulanoudjingar S.S., Fernandes JF, Abossolo BP, Conzelmann C, Methogo B.G., Doucka Y., Flamen A, Mordmüller B, et al.; RTS, S Clinical Trials Partnership. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med 2011; 365: 1863-75; PMID: 22007715; http://dx.doi.org/10.1056/NEJMoa1102287
9. Bejon P, Cook J, Bergmann-Leitner E, Olotu A., Lusingu J, Mwacharo J, Vekemans J., Njuguna P, Leach A, Lievens M., et al. Effect of the pre-eryth-rocytic candidate malaria vaccine RTS, S/AS01E on blood stage immunity in young children. J Infect Dis 2011; 204: 9-18; PMID: 21628653; http://dx.doi.org/10.1093/infdis/jir222
10. Olotu A, Moris P, Mwacharo J., Vekemans J, Kimani D, Janssens M., Kai O, Jongert E, Lievens M., Leach A, et al. Circumsporozoite-specific T cell responses in children vaccinated with RTS, S/AS01E and protection against P falciparum clinical malaria. PLoS One 2011; 6: e25786; PMID: 21998698; http://dx.doi.org/10.1371/journal.pone.0025786
11. Olotu A, Lusingu J, Leach A., Lievens M, Vekemans J, Msham S., Lang T, Gould J, Dubois M.C., Jongert E., et al. Efficacy of RTS, S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: A randomised controlled trial. Lancet Infect Dis 2011; 11: 102-9; PMID: 21237715; http://dx.doi.org/10.1016/S1473-3099(10)70262-0
12. Aide P, Dobaño C, Sacarlal J., Aponte JJ, Mandomando I, Guinovart C, Bassat Q., Renom M, Puyol L, Macete E., et al. Four year immunogenicity of the RTS, S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial. Vaccine 2011; 29: 6059-67; PMID: 21443960; http://dx.doi.org/10.1016/j. vaccine.2011.03.041
13. Bojang KA, Milligan PJ, Pinder M, Vigneron L., Alloueche A, Kester KE, Ballou W.R., Conway DJ, Reece WH, Gothard P, et al.; RTS, S Malaria Vaccine Trial Team. Efficacy of RTS, S/AS02 malaria vaccine against Plasmodium falciparum infection in semiimmune adult men in The Gambia: A randomised trial. Lancet 2001; 358: 1927-34; PMID: 11747915; http://dx.doi.org/10.1016/S0140- 6736(01)06957-4 (Pubitemid 34072872)
14. Stoute JA, Kester KE, Krzych U, Wellde B.T., Hall T., White K, Glenn G, Ockenhouse C.F., Garcon N., Schwenk R, et al. Long-term efficacy and immune responses following immunization with the RTS, S malaria vaccine. J Infect Dis 1998; 178: 1139-44; PMID: 9806046; http://dx.doi.org/10.1086/515657 (Pubitemid 28452210)
15. Bejon P, Lusingu J, Olotu A., Leach A, Lievens M, Vekemans J., Mshamu S, Lang T, Gould J., Dubois MC, et al. Efficacy of RTS, S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008; 359: 2521-32; PMID: 19064627; http://dx.doi.org/10.1056/NEJMoa0807381
16. Ophorst OJ, Radosević K, Havenga MJ, Pau MG, Holterman L, Berkhout B., Goudsmit J, Tsuji M. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect Immun 2006; 74: 313-20; PMID: 16368986; http://dx.doi.org/10.1128/IAI.74. 1.313-320.2006 (Pubitemid 43023087)
17. Stewart VA, McGrath SM, Dubois P.M., Pau MG, Mettens P, Shott J, Cobb M., Burge JR, Larson D, Ware LA, et al. Priming with an adenovirus 35-cir-cumsporozoite protein (CS) vaccine followed by RTS, S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect Immun 2007; 75: 2283-90; PMID: 17307942; http://dx.doi.org/10.1128/IAI.01879-06 (Pubitemid 46744316)
18. Shott JP, McGrath SM, Pau M.G., Custers JH, Ophorst O, Demoitié MA, Dubois MC, Komisar J, Cobb M., Kester KE, et al. Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumspo-rozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice. Vaccine 2008; 26: 2818-23; PMID: 18455276; http://dx.doi.org/10.1016/j.vaccine. 2008.03.080
19. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I., de Béthune MP, Kostense S, Penders G., Helmus N, Koudstaal W, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003; 77: 8263-71; PMID: 12857895; http://dx.doi.org/10.1128/ JVI.77.15.8263-8271.2003 (Pubitemid 36871454)
20. Ophorst OJ, Kostense S, Goudsmit J., De Swart RL, Verhaagh S, Zakhartchouk A, Van Meijer M, Sprangers M, Van Amerongen G, Yüksel S, et al. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine 2004; 22: 3035-44; PMID: 15297053; http://dx.doi.org/10.1016/j.vaccine.2004.02.011 (Pubitemid 39037205)
21. Peiperl L, Morgan C, Moodie Z., Li H, Russell N, Graham B.S., Tomaras GD, De Rosa SC, McElrath MJ; NIAID HIV Vaccine Trials Network. Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: A randomized clinical trial (HVTN 054). PLoS One 2010; 5: e13579; PMID: 21048953; http://dx.doi.org/10.1371/journal.pone.0013579
22. Schuldt NJ, Aldhamen YA, Godbehere-Roosa S, Seregin S.S., Kousa YA, Amalfitano A. Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and adenovirus (Ad5) immune mice. Malar J 2012; 11: 209; PMID: 22720732; http://dx.doi.org/10.1186/1475- 2875-11-209
23. Schuldt NJ, Amalfitano A. Malaria vaccines: focus on adenovirus based vectors. Vaccine 2012; 30: 5191-8; PMID: 22683663; http://dx.doi.org/10.1016/j. vaccine.2012.05.048
24. Rodrigues EG, Zavala F, Nussenzweig R.S., Wilson JM, Tsuji M. Efficient induction of protective antimalaria immunity by recombinant adenovirus. Vaccine 1998; 16: 1812-7; PMID: 9795385; http://dx.doi.org/10.1016/S0264-410X(98)00181-9 (Pubitemid 28473920)
25. Radosevic K, Rodriguez A, Lemckert A.A., van der Meer M, Gillissen G, Warnar C, von Eyben R, Pau MG, Goudsmit J. The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clin Vaccine Immunol 2010; 17: 1687-94; PMID: 20826614; http://dx.doi.org/10.1128/CVI.00311-10
26. Chuang I, Sedegah M, Cicatelli S., Spring M, Polhemus M, Tamminga C., Patterson N, Guerrero M, Bennett J.W., McGrath S., et al. DNA prime/Adenovirus boost malaria vaccine encoding P. fal-ciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One 2013; 8: e55571; PMID: 23457473; http://dx.doi.org/10.1371/journal.pone.0055571
27. Tamminga C, Sedegah M, Regis D., Chuang I, Epstein JE, Spring M, Mendoza-Silveiras J, McGrath S., Maiolatesi S, Reyes S, et al. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One 2011; 6: e25868; PMID: 22003411; http://dx.doi.org/10.1371/jour-nal.pone.0025868
28. Sedegah M, Tamminga C, McGrath S., House B, Ganeshan H, Lejano J., Abot E, Banania GJ, Sayo R, Farooq F., et al. Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS One 2011; 6: e24586; PMID: 22003383; http://dx.doi.org/10.1371/journal.pone.0024586
29. + T cell-mediated protective anti-malaria immunity elicited by recombinant adenovirus. Parasite Immunol 2000; 22: 157-60; PMID: 10672197; http://dx.doi.org/10.1046/j.1365-3024.2000.00289.x (Pubitemid 30137757)
30. Agnandji ST, Lell B, Fernandes J.F., Abossolo BP, Methogo BG, Kabwende AL, Adegnika A.A., Mordmüller B, Issifou S., Kremsner PG, et al.; RTS, S Clinical Trials Partnership. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N Engl J Med 2012; 367: 2284-95; PMID: 23136909; http://dx.doi.org/10.1056/NEJMoa1208394
31. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I., de Béthune MP, Kostense S, Penders G., Helmus N, Koudstaal W, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003; 77: 8263-71; PMID: 12857895; http://dx.doi.org/10.1128/ JVI.77.15.8263-8271.2003 (Pubitemid 36871454)
32. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald D.W., Mogg R., Li D, Gilbert PB, Lama J.R., Marmor M., Del Rio C, et al.; Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1881-93; PMID: 19012954; http://dx.doi.org/10.1016/S0140-6736(08) 61591-3
33. Ledgerwood JE, Costner P, Desai N., Holman L, Enama ME, Yamshchikov G, Mulangu S., Hu Z, Andrews CA, Sheets R.A., et al.; VRC 205 Study Team. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immuno-genic in healthy adults. Vaccine 2010; 29: 304-13; PMID: 21034824; http://dx.doi.org/10.1016/j.vaccine.2010.10.037
34. Radosevic K, Rodriguez A, Lemckert A.A., van der Meer M, Gillissen G, Warnar C., von Eyben R, Pau MG, Goudsmit J. The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clin Vaccine Immunol 2010; 17: 1687-94; PMID: 20826614; http://dx.doi.org/10.1128/CVI.00311-10
35. Maizel JV Jr., White DO, Scharff MD. The polypep-tides of adenovirus. II. Soluble proteins, cores, top components and the structure of the virion. Virology 1968; 36: 126-36; PMID: 5669983; http://dx.doi.org/10.1016/0042- 6822(68)90122-0
36. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L., Janes H, Defawe OD, Carter D.K., Hural J., Akondy R, et al.; Step Study Protocol Team. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: A case-cohort analysis. Lancet 2008; 372: 1894-905; PMID: 19012957; http://dx.doi.org/10.1016/ S0140-6736(08)61592-5
37. Kostense S, Mommaas B, Hendriks J., Verhoeven M, Ter Haak M, Tirion F, Wiesken E., Pau MG, Radosevic K, Goudsmit J. A peptide-based Plasmodium falciparum circumsporozoite assay to test for serum antibody responses to pre-eryth-rocyte malaria vaccines. Clin Vaccine Immunol 2011; 18: 776-82; PMID: 21411600; http://dx.doi.org/10.1128/CVI.00547-10
38. Rock MT, Yoder SM, Talbot T.R., Edwards KM, Crowe JE Jr. Cellular immune responses to diluted and undiluted aventis pasteur smallpox vaccine. J Infect Dis 2006; 194: 435-43; PMID: 16845626; http://dx.doi.org/10.1086/505506 (Pubitemid 44162654)
39. Rock MT, Yoder SM, Wright P.F., Talbot TR, Edwards KM, Crowe JE Jr. Differential regulation of granzyme and perforin in effector and memory T cells following smallpox immunization. J Immunol 2005; 174: 3757-64; PMID: 15749916 (Pubitemid 40354088)
40. + cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus. Virology 2005; 337: 335-43; PMID: 15916793; http://dx.doi.org/10.1016/j.virol.2005.04.032 (Pubitemid 40799001)
41. z.ast;01-restricted cyto-toxic T-lymphocyte epitope in the respiratory syn-cytial virus fusion protein. Immunology 2003; 108: 474-80; PMID: 12667209; http://dx.doi.org/10.1046/j.1365-2567.2003.01619.x (Pubitemid 36469685)